Similar articles

• Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.

  Madsen S. Madsen S. Acta Med Scand Suppl. 1980;638:3-120. Acta Med Scand Suppl. 1980. PMID: 6929650 No abstract available.
• [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].

  Sebert JL, Marie A, Kuntz D, Marie P, Gueris J, Smadja A, Fournier A, Quichaud J. Sebert JL, et al. Rev Rhum Mal Osteoartic. 1981 Jul-Sep;48(7-9):535-41. Rev Rhum Mal Osteoartic. 1981. PMID: 7291931 French.
• 1alpha-Hydroxycholecalciferol in renal osteodystrophy.

  Pierides AM, Ellis HA, Ward MK, Simpson W, Kerr DN. Pierides AM, et al. Calcif Tissue Res. 1977 May;22 Suppl:105-11. doi: 10.1007/BF02064049. Calcif Tissue Res. 1977. PMID: 912511 No abstract available.
• Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

  Massry SG, Goldstein DA, Malluche HH. Massry SG, et al. Kidney Int. 1980 Oct;18(4):409-18. doi: 10.1038/ki.1980.154. Kidney Int. 1980. PMID: 7014981 Review. No abstract available.
• Are new vitamin D analogues in renal bone disease superior to calcitriol?

  Salusky IB. Salusky IB. Pediatr Nephrol. 2005 Mar;20(3):393-8. doi: 10.1007/s00467-004-1788-2. Epub 2005 Feb 3. Pediatr Nephrol. 2005. PMID: 15690188 Review.